基于基础疗法的芪苈强心胶囊综合用药对慢性充血性心力衰竭患者HR、LVEF、LVEDD水平的影响
|
摘要
目的:研究基于基础疗法的芪苈强心胶囊综合用药对慢性充血性心力衰竭患者心率(HR)、左室射血分数(LVEF)、左室舒张末期内径(LVEDD)水平的影响。方法:选取2016年1月至2018年1月山东省滨州市人民医院收治的慢性充血性心力衰竭患者94例,按照随机数字表法平均分为对照组和观察组,每组47例。对照组予以常规治疗,观察组则在常规治疗的基础上予以芪苈强心胶囊治疗。分别比较2组临床疗效,治疗前后HR、LVEF、LVEDD水平,治疗前后VEGF、NO水平以及血浆AngⅡ、ET、BNP水平。结果:观察组总有效率为91. 49%(43/47),高于对照组的72. 34%(34/47),差异有统计学意义(P <0. 05)。治疗后观察组HR、LVEDD水平分别为(76. 43±6. 52)次/min、(46. 12±4. 08) mm,低于对照组的(88. 61±7. 33)次/min、(50. 13±4. 33) mm,而LVEF水平为(42. 30±7. 01)%,高于对照组的(36. 72±6. 11)%,差异均有统计学意义(均P <0. 05)。治疗后观察组VEGF、NO水平分别为(522. 58±127. 57) ng/L、(43. 49±7. 01)μmol/L,高于对照组的(441. 38±113. 52) ng/L、(34. 85±6. 88)μmol/L,差异均有统计学意义(均P <0. 05)。治疗后观察组血浆AngⅡ、ET、BNP水平分别为(135. 42±24. 48) pg/m L、(53. 68±22. 82) ng/L、(287. 96±62. 02)μg/L,低于对照组的(161. 33±23. 66) pg/m L、(84. 68±27. 48) ng/L、(372. 02±64. 86)μg/L,差异均有统计学意义(均P <0. 05)。结论:基于基础疗法的芪苈强心胶囊综合用药治疗慢性充血性心力衰竭疗效明显,有利于促进患者心功能恢复,同时有效改善血管内皮功能。
Objective: To study the effects of Qili Qiangxin Capsule based on basic therapy on HR,LVEF and LVEDD levels in patients with chronic congestive heart failure. Methods: A total of 94 patients with chronic congestive heart failure admitted to Binzhou People's Hospital of Shandong Province from January 2016 to January 2018 were studied. All patients were divided into observation group and control group by random number table method. The control group was treated with routine treatment,and the observation group was treated with Qili Qiangxin Capsule on the basis of routine treatment. Respectively,2 groups of clinical curative effect,HR,LVEF and LVEDD level before and after the treatment,VEGF and NO level before and after treatment and plasma Ang Ⅱ,ET,the BNP level were compared. Results: The total effective rate of the observation group was 91. 49%( 43/47),which was higher than 72. 34%( 34/47) of the control group,and the difference was statistically significant( P < 0. 05). The observation group of HR,LVEDD after treatment was( 76. 43 ± 6. 52) times/min,( 46. 12 ± 4. 08) mm,which was lower than the control group of( 88. 61 ± 7. 33) times/min,( 50. 13 ± 4. 33) mm,and LVEF level was( 42. 30 ± 7. 01) %,which was higher than the control group( 36. 72 ± 6. 11) %,the difference was statistically significant( all P < 0. 05). After treatment,VEGF and NO levels in the observation group were( 522. 58 ± 127. 57) ng/L,( 43. 49 ± 7. 01) μmol/L,which was higher than the control group of( 441. 38± 113. 52) ng/L and( 34. 85 ± 6. 88) μmol/L,the difference was statistically significant( all P < 0. 05). The observation group after treatment of plasma Ang Ⅱ,ET,BNP levels were( 135. 42 ± 24. 48) pg/m L,( 53. 68 ± 22. 82) ng/L,( 287. 96 ± 62. 02) μg/L,which was lower than the control group of( 161. 33 ± 23. 66) pg/m L,( 84. 68 ± 27. 48) ng/L,( 372. 02 ± 64. 86) μg/L,the difference was statistically significant( all P < 0. 05). Conclusion: Qili Qiangxin Capsule based on basic therapy has obvious curative effect in the treatment of chronic congestive heart failure,which is conducive to the recovery of patients' heart function and the effective improvement of vascular endothelial function.
Objective: To study the effects of Qili Qiangxin Capsule based on basic therapy on HR,LVEF and LVEDD levels in patients with chronic congestive heart failure. Methods: A total of 94 patients with chronic congestive heart failure admitted to Binzhou People's Hospital of Shandong Province from January 2016 to January 2018 were studied. All patients were divided into observation group and control group by random number table method. The control group was treated with routine treatment,and the observation group was treated with Qili Qiangxin Capsule on the basis of routine treatment. Respectively,2 groups of clinical curative effect,HR,LVEF and LVEDD level before and after the treatment,VEGF and NO level before and after treatment and plasma Ang Ⅱ,ET,the BNP level were compared. Results: The total effective rate of the observation group was 91. 49%( 43/47),which was higher than 72. 34%( 34/47) of the control group,and the difference was statistically significant( P < 0. 05). The observation group of HR,LVEDD after treatment was( 76. 43 ± 6. 52) times/min,( 46. 12 ± 4. 08) mm,which was lower than the control group of( 88. 61 ± 7. 33) times/min,( 50. 13 ± 4. 33) mm,and LVEF level was( 42. 30 ± 7. 01) %,which was higher than the control group( 36. 72 ± 6. 11) %,the difference was statistically significant( all P < 0. 05). After treatment,VEGF and NO levels in the observation group were( 522. 58 ± 127. 57) ng/L,( 43. 49 ± 7. 01) μmol/L,which was higher than the control group of( 441. 38± 113. 52) ng/L and( 34. 85 ± 6. 88) μmol/L,the difference was statistically significant( all P < 0. 05). The observation group after treatment of plasma Ang Ⅱ,ET,BNP levels were( 135. 42 ± 24. 48) pg/m L,( 53. 68 ± 22. 82) ng/L,( 287. 96 ± 62. 02) μg/L,which was lower than the control group of( 161. 33 ± 23. 66) pg/m L,( 84. 68 ± 27. 48) ng/L,( 372. 02 ± 64. 86) μg/L,the difference was statistically significant( all P < 0. 05). Conclusion: Qili Qiangxin Capsule based on basic therapy has obvious curative effect in the treatment of chronic congestive heart failure,which is conducive to the recovery of patients' heart function and the effective improvement of vascular endothelial function.
引文
[1]Shirakabe A,Hata N,Kobayashi N,et al.Clinical Usefulness of Urinary Liver Fatty Acid-Binding Protein Excretion for Predicting Acute Kidney Injury during the First 7 Days and the Short-Term Prognosis in Acute Heart Failure Patients with Non-Chronic Kidney Disease[J].Cardiorenal Med,2017,7(4):301-315.
[2]马柳一,尹玉洁,张军芳,等.芪苈强心胶囊对慢性心衰大鼠下丘脑室旁核RAS系统及交感神经系统的影响[J].中国药理学通报,2016,32(4):575-580.
[3]全振华,艾民,金娟,等.芪苈强心胶囊对慢性心衰的治疗作用及机制的研究进展[J].中医药学报,2016,44(2):108-110.
[4]中华医学会心血管病学分会.中国心力衰竭诊断和治疗指南2014[J].中华心血管病杂志,2014,42(2):3-10.
[5]熊伟平,黄高忠.慢性心力衰竭患者血清25-羟维生素D3水平检测及其意义[J].中华老年多器官疾病杂志,2017,16(11):832-836.
[6]高鹏,寇广亚,武延海,等.托伐普坦治疗老年慢性充血性心力衰竭合并低钠血症及利尿剂抵抗的近期疗效[J].中国循证心血管医学杂志,2017,9(2):159-163.
[7]冯健,钟毅,李家富,等.环磷腺苷葡胺联合芪苈强心胶囊治疗慢性心力衰竭34例疗效分析[J].实用中西医结合临床,2015,15(2):11-12.
[8]Wojtczak-Soska K,Sakowicz A,Pietrucha T,et al.Soluble ST2 protein and hospitalizations due to worsening chronic heart failureduring a oneyear follow-up in a population with reduced ejection fraction[J].Adv Clin Exp Med,2017,26(6):931-938.
[9]陆勇良,姚超永,陈海健,等.小剂量螺内酯联合常规治疗对慢性充血性心力衰竭的效果[J].临床医学工程,2017,24(9):1239-1240.
[10]宋涛,宋敏,李勇,等.等渗造影剂对慢性充血性心力衰竭患者介入治疗后肾功能的影响[J].中国医师进修杂志,2017,40(2):107-110.
[11]胡霜,蔡莉,张川平,等.美托洛尔联合芪苈强心胶囊治疗慢性心力衰竭的疗效观察[J].重庆医学,2017,46(5):589-591.
[12]李定国.芪苈强心胶囊对慢性心衰患者的临床效果观察[J].临床医学研究与实践,2017,2(6):33-34.
[13]李楠.芪苈强心胶囊治疗冠心病慢性心衰阳气亏虚、血瘀水停证的临床观察[J].中西医结合心血管病(连续型电子期刊),2017,5(33):134-134.
[14]张小丹.硝普钠联合芪苈强心胶囊治疗慢性充血性心衰的临床观察[J].实用中西医结合临床,2017,17(12):63-64.
[15]赵自瑞.芪苈强心胶囊治疗慢性充血性心力衰竭的临床研究[J].中国现代医生,2015,53(30):88-90.
[16]张霞.芪苈强心胶囊治疗慢性充血性心力衰竭疗效观察[J].中国实用医刊,2012,39(13):108-109.
[17]刘芳,王常林.益气活血方对气虚血瘀型慢性心衰的治疗效果及可能机理[J].中药材,2017,40(1):230-232.
[2]马柳一,尹玉洁,张军芳,等.芪苈强心胶囊对慢性心衰大鼠下丘脑室旁核RAS系统及交感神经系统的影响[J].中国药理学通报,2016,32(4):575-580.
[3]全振华,艾民,金娟,等.芪苈强心胶囊对慢性心衰的治疗作用及机制的研究进展[J].中医药学报,2016,44(2):108-110.
[4]中华医学会心血管病学分会.中国心力衰竭诊断和治疗指南2014[J].中华心血管病杂志,2014,42(2):3-10.
[5]熊伟平,黄高忠.慢性心力衰竭患者血清25-羟维生素D3水平检测及其意义[J].中华老年多器官疾病杂志,2017,16(11):832-836.
[6]高鹏,寇广亚,武延海,等.托伐普坦治疗老年慢性充血性心力衰竭合并低钠血症及利尿剂抵抗的近期疗效[J].中国循证心血管医学杂志,2017,9(2):159-163.
[7]冯健,钟毅,李家富,等.环磷腺苷葡胺联合芪苈强心胶囊治疗慢性心力衰竭34例疗效分析[J].实用中西医结合临床,2015,15(2):11-12.
[8]Wojtczak-Soska K,Sakowicz A,Pietrucha T,et al.Soluble ST2 protein and hospitalizations due to worsening chronic heart failureduring a oneyear follow-up in a population with reduced ejection fraction[J].Adv Clin Exp Med,2017,26(6):931-938.
[9]陆勇良,姚超永,陈海健,等.小剂量螺内酯联合常规治疗对慢性充血性心力衰竭的效果[J].临床医学工程,2017,24(9):1239-1240.
[10]宋涛,宋敏,李勇,等.等渗造影剂对慢性充血性心力衰竭患者介入治疗后肾功能的影响[J].中国医师进修杂志,2017,40(2):107-110.
[11]胡霜,蔡莉,张川平,等.美托洛尔联合芪苈强心胶囊治疗慢性心力衰竭的疗效观察[J].重庆医学,2017,46(5):589-591.
[12]李定国.芪苈强心胶囊对慢性心衰患者的临床效果观察[J].临床医学研究与实践,2017,2(6):33-34.
[13]李楠.芪苈强心胶囊治疗冠心病慢性心衰阳气亏虚、血瘀水停证的临床观察[J].中西医结合心血管病(连续型电子期刊),2017,5(33):134-134.
[14]张小丹.硝普钠联合芪苈强心胶囊治疗慢性充血性心衰的临床观察[J].实用中西医结合临床,2017,17(12):63-64.
[15]赵自瑞.芪苈强心胶囊治疗慢性充血性心力衰竭的临床研究[J].中国现代医生,2015,53(30):88-90.
[16]张霞.芪苈强心胶囊治疗慢性充血性心力衰竭疗效观察[J].中国实用医刊,2012,39(13):108-109.
[17]刘芳,王常林.益气活血方对气虚血瘀型慢性心衰的治疗效果及可能机理[J].中药材,2017,40(1):230-232.